other material
confidence high
sentiment positive
materiality 0.75
PharmaCyte raises $7M in private placement of Series C convertible preferred and warrants
PharmaCyte Biotech, Inc.
- Sale of 7,000 shares of Series C preferred (stated value $1,000) convertible into 7M common at $1.00 per share.
- Warrants to purchase 7M common shares at $1.00, exercisable immediately for 5 years.
- Preferred shares accrue a 7% quarterly dividend payable in cash; 15% upon trigger event.
- Company must seek stockholder approval by Oct 31, 2025 to issue >19.99% of outstanding common.
- Proceeds used for general corporate purposes and working capital; closing expected Aug 19, 2025.